Pharmaceutical protein production by yeast: towards production of human blood proteins by microbial fermentation
Journal article, 2012

Since the approval of recombinant insulin from Escherichia coli for its clinical use in the early 1980s, the amount of recombinant pharmaceutical proteins obtained by microbial fermentations has significantly increased. The recent advances in genomics together with high throughput analysis techniques (the so-called - omics approaches) and integrative approaches (systems biology) allow the development of novel microbial cell factories as valuable platforms for large scale production of therapeutic proteins. This review summarizes the main achievements and the current situation in the field of recombinant therapeutics using yeast Saccharomyces cerevisiae as a model platform, and discusses the future potential of this platform for production of blood proteins and substitutes.

systems

alpha-hemoglobin

human serum-albumin

therapeutic proteins

human hemoglobin

heterologous proteins

expression

escherichia-coli

pichia-pastoris

filamentous fungi

saccharomyces-cerevisiae

Author

Jose Luis Martinez Ruiz

Chalmers, Chemical and Biological Engineering, Life Sciences, System Biology

Lifang Liu

Chalmers, Chemical and Biological Engineering, Life Sciences, System Biology

Dina Petranovic Nielsen

Chalmers, Chemical and Biological Engineering, Life Sciences, System Biology

Jens B Nielsen

Chalmers, Chemical and Biological Engineering, Life Sciences, System Biology

Current Opinion in Biotechnology

0958-1669 (ISSN)

Vol. 23 6 965-971

Industrial Systems Biology of Yeast and A. oryzae (INSYSBIO)

European Commission (FP7), 2010-01-01 -- 2014-12-31.

Areas of Advance

Life Science Engineering (2010-2018)

Subject Categories

Chemical Sciences

DOI

10.1016/j.copbio.2012.03.011

More information

Created

10/7/2017